Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8(+) T cell activation in the presence of adjuvant temozolomide

In a two-stage phase II study, 24 patients with first diagnosis of glioblastoma (GBM) were treated with dendritic cell (DC) immunotherapy associated to standard radiochemotherapy with temozolomide (TMZ) followed by adjuvant TMZ. Three intradermal injections of mature DC loaded with autologous GBM ly...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncoimmunology
Päätekijät: Pellegatta, Serena, Eoli, Marica, Cuccarini, Valeria, Anghileri, Elena, Pollo, Bianca, Pessina, Sara, Frigerio, Simona, Servida, Maura, Cuppini, Lucia, Antozzi, Carlo, Cuzzubbo, Stefania, Corbetta, Cristina, Paterra, Rosina, Acerbi, Francesco, Ferroli, Paolo, DiMeco, Francesco, Fariselli, Laura, Parati, Eugenio A., Bruzzone, Maria Grazia, Finocchiaro, Gaetano
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Taylor & Francis 2018
Aiheet:
Original Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5889286/
https://ncbi.nlm.nih.gov/pubmed/29632727
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1412901
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia